
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
An scientist's accident has led to the development of a blood-clotting powder that works on contact and reportedly is being sold at CVS and Walgreens.






